These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 24927813)

  • 1. Genetic inhibition of the atypical kinase Wee1 selectively drives apoptosis of p53 inactive tumor cells.
    Pappano WN; Zhang Q; Tucker LA; Tse C; Wang J
    BMC Cancer; 2014 Jun; 14():430. PubMed ID: 24927813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour suppressive effects of WEE1 gene silencing in breast cancer cells.
    Ghiasi N; Habibagahi M; Rosli R; Ghaderi A; Yusoff K; Hosseini A; Abdullah S; Jaberipour M
    Asian Pac J Cancer Prev; 2014 Jan; 14(11):6605-11. PubMed ID: 24377575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy.
    Clausse V; Goloudina AR; Uyanik B; Kochetkova EY; Richaud S; Fedorova OA; Hammann A; Bardou M; Barlev NA; Garrido C; Demidov ON
    Cell Death Dis; 2016 Apr; 7(4):e2195. PubMed ID: 27077811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation.
    Davies KD; Cable PL; Garrus JE; Sullivan FX; von Carlowitz I; Huerou YL; Wallace E; Woessner RD; Gross S
    Cancer Biol Ther; 2011 Nov; 12(9):788-96. PubMed ID: 21892012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors.
    Li Y; Saini P; Sriraman A; Dobbelstein M
    Oncotarget; 2015 Oct; 6(32):32339-52. PubMed ID: 26431163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WEE1 inhibition sensitizes osteosarcoma to radiotherapy.
    PosthumaDeBoer J; Würdinger T; Graat HC; van Beusechem VW; Helder MN; van Royen BJ; Kaspers GJ
    BMC Cancer; 2011 Apr; 11():156. PubMed ID: 21529352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.
    Zhou L; Zhang Y; Chen S; Kmieciak M; Leng Y; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Dai Y; Grant S
    Leukemia; 2015 Apr; 29(4):807-18. PubMed ID: 25283841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.
    Hirai H; Iwasawa Y; Okada M; Arai T; Nishibata T; Kobayashi M; Kimura T; Kaneko N; Ohtani J; Yamanaka K; Itadani H; Takahashi-Suzuki I; Fukasawa K; Oki H; Nambu T; Jiang J; Sakai T; Arakawa H; Sakamoto T; Sagara T; Yoshizumi T; Mizuarai S; Kotani H
    Mol Cancer Ther; 2009 Nov; 8(11):2992-3000. PubMed ID: 19887545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome.
    Murrow LM; Garimella SV; Jones TL; Caplen NJ; Lipkowitz S
    Breast Cancer Res Treat; 2010 Jul; 122(2):347-57. PubMed ID: 19821025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor.
    Mizuarai S; Yamanaka K; Itadani H; Arai T; Nishibata T; Hirai H; Kotani H
    Mol Cancer; 2009 Jun; 8():34. PubMed ID: 19500427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional kinomics identifies candidate therapeutic targets in head and neck cancer.
    Moser R; Xu C; Kao M; Annis J; Lerma LA; Schaupp CM; Gurley KE; Jang IS; Biktasova A; Yarbrough WG; Margolin AA; Grandori C; Kemp CJ; Méndez E
    Clin Cancer Res; 2014 Aug; 20(16):4274-88. PubMed ID: 25125259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.
    Carrassa L; Chilà R; Lupi M; Ricci F; Celenza C; Mazzoletti M; Broggini M; Damia G
    Cell Cycle; 2012 Jul; 11(13):2507-17. PubMed ID: 22713237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma.
    Harris PS; Venkataraman S; Alimova I; Birks DK; Balakrishnan I; Cristiano B; Donson AM; Dubuc AM; Taylor MD; Foreman NK; Reigan P; Vibhakar R
    Mol Cancer; 2014 Mar; 13():72. PubMed ID: 24661910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells.
    Kreahling JM; Gemmer JY; Reed D; Letson D; Bui M; Altiok S
    Mol Cancer Ther; 2012 Jan; 11(1):174-82. PubMed ID: 22084170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WEE1 kinase inhibitor MK-1775 sensitizes oral tongue squamous cell carcinoma cells to radiation irrespective of TP53 status.
    Al-Jamaei AH; de Visscher JGAM; Subramanyam VR; Forouzanfar T; Sminia P; Doulabi BZ; Helder MN
    Oral Dis; 2023 Oct; 29(7):2640-2649. PubMed ID: 35672254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokinetic effects of Wee1 disruption in pancreatic cancer.
    Chang Q; Chandrashekhar M; Ketela T; Fedyshyn Y; Moffat J; Hedley D
    Cell Cycle; 2016; 15(4):593-604. PubMed ID: 26890070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour suppressive effects of WEE1 gene silencing in neuroblastomas.
    Tashnizi AH; Jaberipour M; Razmkhah M; Rahnama S; Habibagahi M
    J Cancer Res Ther; 2016; 12(1):221-7. PubMed ID: 27072241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis.
    Mak JP; Man WY; Ma HT; Poon RY
    Oncotarget; 2014 Nov; 5(21):10546-57. PubMed ID: 25301733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1.
    Creevey L; Ryan J; Harvey H; Bray IM; Meehan M; Khan AR; Stallings RL
    Mol Cancer; 2013 Mar; 12():23. PubMed ID: 23531080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
    Guertin AD; Li J; Liu Y; Hurd MS; Schuller AG; Long B; Hirsch HA; Feldman I; Benita Y; Toniatti C; Zawel L; Fawell SE; Gilliland DG; Shumway SD
    Mol Cancer Ther; 2013 Aug; 12(8):1442-52. PubMed ID: 23699655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.